Welcome to Our Website!

The AIDS Malignancy
Consortium (AMC) is a National Cancer Institute-supported
clinical trials group founded in 1995 to support innovative
trials for AIDS-related cancers. The AMC is composed of 36
Clinical Trials Sites worldwide, five Working Groups, an
Administrative Office, a Statistical Office, and an
Operations and Data Management Office. Collectively, these
components develop and oversee the scientific agenda, manage
the groups’ portfolio of clinical trials and other
scientific-based studies, and help to develop new protocols.
The AMC mission is to investigate new treatment and
prevention interventions for malignancies in people living
with HIV and to study the pathobiology of these tumors in
the context of clinical trials.

Four of the working
groups deal with the cancers that affect HIV-positive
patients—Kaposi’s Sarcoma, Lymphoma, Human Papillomavirus-related
Cancers (for example, anal and cervical cancers), and
Non-AIDS Defining Cancers (for example, lung cancer, head
and neck cancer, liver cancer). The Laboratory Working Group
oversees the Central Laboratories of the AMC and develops
laboratory studies to answer important scientific questions
related to cancer in HIV-positive patients. In addition, all
of the groups within the AMC are working to expand the AMC
globally and to conduct clinical trials for AIDS-related
cancers in diverse patient populations.

We invite you to
explore the AMC Website, and we actively seek your
input/feedback.

Human Papillomavirus Vaccine Proves Effective in Women With HIV A study of HIV-infected women in the United States, Brazil, and South Africa has found that the quadrivalent HPV vaccine was safe and immunogenic against HPV types 6, 11, 16, and 18, even if the women had had HIV for years. The study by Kojic et al is published in Clinical Infectious Diseases.